Validation of Chlamydia Diagnostic Codes in TriNetX US EHR Data
Recruiting
Observational Study
Chlamydial Infections
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 14 – 44
- Sex
- Any
- Study type
- Observational
- Participants needed
- 533,000 (estimated)
- Sponsor
- Sanofi · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study is a pharmacoepidemiologic method study based on the secondary use of pre-existing data that examines whether TriNetX, a global health research network encompassing a worldwide electronic health record (EHR), database in the US is an appropriate real-world data (RWD) source for conducting chlamydia-related research to support the chlamydia trachomatis (CT) messenger Ribonucleic acid (mR…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria for Primary Objectives:
* Patients with an ICD-10-CM diagnosis of chlamydia documented in their EHR OR patients with a nucleic acid amplification test (NAAT) result for chlamydia (either positive or negative) during the study period. The index date is the date of the first-record…
Contacts
Trial Transparency email recommended (Toll free for US & Canada)
800-633-1610
CONTACT